Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

Moderna received FDA advisory committee approval for its mRNA-based flu vaccine (mRNA-1010) for patients 50+, with potential FDA approval by August 5. The company also announced plans to develop an in vivo CAR-T candidate. However, despite a 150% surge over the past year and bullish sentiment, much of the comeback potential is already priced into the stock. With a $26.7 billion market cap while unprofitable, and the flu vaccine market estimated at only $9.5 billion, investors may want to wait for hype to fade before buying.